Ivogen is a brand that specializes in a novel therapeutic approach to treating pathogenic bacteria. Their mission is to develop a new class of broad-spectrum antibacterial agents that can overcome the limitations of current antibiotics, specifically combating the crisis of multi-antibiotic resistant strains of bacteria that cause severe and life-threatening infections. Unlike conventional antibiotics, Ivogen's drugs inhibit the production of virulence factors that allow bacteria to cause diseases within the host.

These drugs disarm bacteria, making them less harmful and allowing the body's immune system to clear them out of the body. Importantly, they do not affect the good bacteria in our bodies. What sets Ivogen apart is that their drugs do not directly kill bacteria or block their proliferation, reducing selective pressure for generating drug resistance or cross-resistance with current antibiotics.

Their optimized, patent-protected lead compounds have been proven to be effective against both Gram-positive and Gram-negative pathogens in various infection models. With the use of nanotechnology, Ivogen is also developing proprietary formulations for topical, oral, and intravenous administration. By addressing the economic impact of antibiotic-resistant infections, which is projected to cost billions of dollars in excess healthcare costs and lost productivity, Ivogen's drugs offer a potential solution to this global health crisis.

For more information, you can visit their website and explore their publications or get in touch with the Ivogen team directly. Copyright © Ivogen 2019